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Human L-ficolin (P35, ficolin-2) is synthesised in the liver and secreted into the bloodstream where it is one of the major pattern
recognition molecules of plasma/serum. Like other ficolins, it consists of a collagen-like tail region linked to a fibrinogen-related
globular head; a basic triplet subunit arises via a collagen-like triple helix, and this then forms higher multimers (typically a 12-mer,
Mr 400K). Unlike other ficolins, it has a complex set of binding sites arranged within an internal cleft enabling it to recognise a
variety of molecular patterns including acetylated sugars and certain 1,3-β-glucans. It is one of the fewmolecules known to activate
the lectin pathway of complement. Recently, some disease association studies (at either the DNA or protein level) have implicated
L-ficolin in innate immunity, where it might cooperate with pentraxins and collectins. Emerging lines of evidence point to a role
for L-ficolin in respiratory immunity, where its aﬃnity for Pseudomonas aeruginosa could be significant.
1. Introduction
1.1. Discovery. Ficolins were first discovered as transform-
ing growth factor β-binding proteins present in porcine
uterus, characterised by the possession of both fibrinogen-
related and collagen-like domains [1]. However, it was the
description of P35 as an opsonic, GlcNAc-specific lectin
that first indicated that this family could be involved in
innate immunity as pattern recognitionmolecules [2]. A very
similar molecule named L- (for liver) ficolin was indepen-
dently purified from human plasma on GlcNAc-Sepharose
[3]. Both resembled two other previously discovered plasma
proteins: EBP-37, which bound elastin [4], and hucolin,
which bound a corticosteroid derivative [5].
Despite some minor discrepancies in properties, it was
clear that the same protein was being isolated on diﬀerent
aﬃnity matrices, and the term L-ficolin (or ficolin-2) is now
used for this protein with a rather catholic taste in ligands. In
this, as in several other features, it resembles the intensively
studied mannan- (or mannose-) binding lectin [6], but by
definition a ficolin has a fibrinogen-like domain combined
with a collagen-like domain and is therefore not a collectin.
(Collectins combine a collagen-like domain with a C-type
lectin domain and resemble ficolins and C1q in tertiary
structure.)
1.2. The Ficolin Family. Porcine ficolins consist of two ho-
mologous molecules, designated ficolin-α and -β. Although
first discovered in uterine tissue, porcine ficolin-α is more
abundant in liver and blood where two isoforms, “little
ficolin” (Mr∼400 000) and “big ficolin” (Mr∼800 000) were
described [7]. Ficolin-β, with around 80% identity to ficolin-
α, was found to be expressed mainly in neutrophils [8].
A similar situation exists in mice. Ficolin A is present
in liver and blood plasma, while ficolin B (60% identical) is
expressed in bone marrow and spleen and is associated with
macrophages [9, 10].
These findings have prompted the generalisation that
ficolins can be classified into soluble serum ficolins and cell-
bound ficolins whatever the species. This view is supported
by a similar dichotomy in the toad, Xenopus laevis [11]. The
relationships between ficolins in the above species and others
have been reviewed in more detail by Matsushita [12] and by
Garred et al. 2010 [13].
1.3. Human Ficolins. Unlike pigs or mice, humans have three
ficolins, all of which are present in the bloodstream: M-
ficolin (monocyte ficolin or ficolin-1); L-ficolin (liver ficolin
or ficolin-2); and H-ficolin (Hakata antigen or ficolin-3).
M- and L-ficolin have approximately 80% identity in amino
acid sequence; H-ficolin has only about 50% identity with
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Table 1: The human ficolins.
M-ficolin L-ficolin H-ficolin
Molecular size (subunit) 35 K 35K 34K
Molecular size (native) 900K 420K 610K
Location Neutrophils, monocytes > serum liver; serum liver; bile; lung; serum
Chemical specificity Acetylated sugars
acetylated compounds;
LPS; 1,3-β-glucans;
lipoteichoic acids;
elastin; steroids
D-fucose > GlcNAc;
polysaccharide from
A.viridans
Microbial specificity E. coli; S. aureus; S. agalactiae
S. aureus; S. pneumoniae;
S. typhimurium; E. coli;
P. aeruginosa; M. bovis;
G. lamblia; T. cruzi;
A. fumigatus,
A. viridans; T. cruzi
Complement activation Yes Yes Yes
Opsonic activity ? Yes ?
Collagenase sensitivity Yes Yes No
the other two. M-ficolin, predominantly found in monocytes
and granulocytes, is the homologue of murine ficolin-B
and porcine ficolin-β; L-ficolin is the homologue of murine
ficolin-A and porcine ficolin-α [12].
The third human ficolin, the Hakata antigen originally
identified and defined by autoantibodies present in a small
minority of lupus patients, is synthesised in both liver
(secreted into bile as well as blood) and lung (and secreted
into the bronchi). It is the most abundant plasma ficolin and
the most potent at activating complement in vitro [14, 15].
A comparison of the properties of the ficolins is sum-
marised in Table 1. All three have the ability to activate
the lectin pathway of complement, an activity known to
be shared with just two collectins, mannan-binding lectin
(MBL) and CL-L1 [16, 17]. All three ficolins seem to
recognise acetylated sugars like GlcNAc to some degree. L-
ficolin (like MBL) appears to be a major pattern recognition
molecule in human plasma [18]. It has a uniquely complex
set of binding sites, potentially conferring the ability to
recognise and interact with a wide range of microorganisms
[19]. Recently, L-ficolin has been the subject of several
disease association studies, providing evidence that L-ficolin
complements MBL as an important component of innate
immunity in the circulation. The structure, properties and
function(s) of L-ficolin form the remainder of this paper.
2. Genetics
The human L-ficolin gene (FCN2) has been localised to
chromosome 9 (9q34) [20], like the M-ficolin gene but in
contrast to the H-ficolin gene located on chromosome 1.
The L-ficolin gene has eight exons (Figure 1). The first exon
encodes a signal sequence and the first nine N-terminal
residues. Exons 2 and 3 encode a collagen-like region similar
to that found in collectins. The fourth exon encodes a link
or connecting region. Exons five to eight encode a domain
similar in structure to that of the C-terminal portion of the
human fibrinogen β and γ chains that is characterized by the
conservation of 24 mainly hydrophobic amino acid residues.
The FCN2 gene is undoubtedly polymorphic. Hum-
melshoj et al. [21] first described 5 polymorphisms in the
promotor region and 9 in the structural gene from a Danish
population. Compatible results were reported by Herpers
et al. [22], describing 10 single nucleotide polymorphisms
in 1888 Dutch blood donors. A later study compared five
diﬀerent ethnic groups; some ethnic-specific polymorphisms
were noted, but most were found in all populations [23].
Considerable linkage disequilibrium exists between pairs
of promoter and structural gene dimorphisms, complicating
the investigation of the relationship between allele expression
and protein concentration, but such relationships certainly
exist. High concentrations appear to be associated with the
variant (minority) nucleotide at promoter position−4, while
low concentrations are associated with the variant allele at
position 6424 on exon 8 [24, 25]. It is perhaps surprising, and
certainly confusing, that the latter mutation is also associated
with an increased lectin activity (GlcNAc binding). L-ficolin
has several independent activities, however, associated with
a variety of binding sites (see below), and it is unknown if
other activities are aﬀected.
The single nucleotide polymorphisms implicated in
influencing protein concentration in one or more studies are
listed in Table 2. It is clear however that those mutations
have a very modest influence on average L-ficolin values,
each being associated with large and overlapping ranges [25].
Although circulating L-ficolin levels appear to be reasonably
stable in healthy individuals, it remains to be established
if nongenetic influences may have as great or greater an
eﬀect than the FCN2 genotype. For example, we found
that patients treated for haematological malignancies had
significantly lower median serum L-ficolin compared with
healthy controls [26]. Moreover, when studying babies with
sepsis, we have found large diﬀerences in some individuals
with time (unpublished).
Most individuals possess one or two of themost common
five haplotypes, and Munthe-Fog et al. [25] have helpfully
stratified serum L-ficolin concentration according to those
haplotypes. From this analysis, it is apparent that FCN2
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Cysteine-rich domain
Collagen-like domain
Neck region
Fibrinogen-like domain
Exon 1 Exon 2 Exon 3 Exon 4 Exon 5 Exon 6 Exon 7 Exon 8Promoter
−986 −602 −557 −64 −4 +2488
+6359 +6424 +6442
Thr236Met Ala258Ser Ala264fs
Exon 1: signal peptide and start of N-terminal
domain
Exons 2-3: remainder of N-terminal domain
and collagen-like domain
Exon 4: linker region
Exons 5–8: fibrinogen like domain
Figure 1: The human FCN2 gene. The positions of the major single nucleotide polymorphisms are shown. The mutation at +6442 leads to
a deletion (fs = frameshift mutation).
Table 2: Potentially important polymorphisms in the FCN2 gene.
SNP no.
Region and
position
Base
substitution
Amino acid
substitution
rs3124952 promoter −986 A>G —
rs3124953 promoter −602 G>A —
rs3811140 promoter −557 A>G —
rs28969369 promoter −64 A>C —
rs17514136 promoter −4 A>G —
rs17549193 exon 8 +6359 C>T Thr236Met
rs7851696 exon 8 +6424 G>T Ala258Ser
genotype has little value in predicting protein concentration
in individuals. It has been suggested that the huge diﬀerence
in MBL concentration in general between groups with dif-
ferent MBL2 genotypes is woefully inadequate for predicting
serumMBL levels in individuals and that using that approach
is unreliable for inferring diﬀerences in disease cohorts [27].
That limitation is even more true of FCN2 genotyping,
although immunogenetic studies may provide interesting
additional information to L-ficolin protein measurement.
3. Structure
The primary structure is composed of 288 amino acids
forming a gene product of apparent Mr 35 000 after glycosy-
lation [2]. A short N-terminal region implicated in multimer
formation is followed by a series of 19 (Gly-X-Y) repeats
forming the collagen-like region or domain. This is attached
via a short linking sequence to a large globular domain with
a distinctive fold, homologous to the C-terminal domains
found in fibrinogen chains. This fibrinogen-like domain
occurs in several apparently unrelated proteins, including
tenascins, the acetylated sugar-binding tachylectins from a
horseshoe crab (Tachypleus tridentatus) and the sialic acid-
binding lectin from the slug, Limax flavus [28].
The combination of fibrinogen-like domain and
collagen-like region in L-ficolin (and other ficolins) permits
the gene product to form a basic subunit consisting a triple
helical tail and a trio of globular heads. This 3-dimensional
structure is often likened to a bowl of tulips and resembles
the shape of the complement component C1q and the
collectin family despite those other molecules not having
primary sequence homology with ficolins or with each
other. The triplet subunits can then associate to form higher
multimers (Figure 2). The major form in plasma is believed
to be a tetramer of subunits (12-mer) with an apparent Mr
of approximately 400 000 [10, 29].
L-ficolin uniquely possesses a complex set of binding sites
constituting a recognition surface that can detect various
acetylated structures and neutral sugars in the context
of extended polysaccharides. This conclusion is based on
studies of its trimeric recombinant recognition domains
solved by X-ray crystallography [19, 30]. There is an outer
binding site (S1) close to the only calcium binding site.
This could be considered the ancestral binding site, as it is
homologous to that of the horseshoe crab tachylectin 5A as
well as that found in human H- and M-ficolins. Surprisingly,
S1 is not responsible for recognition of acetylated sugars
unlike its counterpart in tachylectin 5A. Instead, L-ficolin
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Figure 2: L-ficolin structure. The glycosylated gene product of Mr
35K forms a basic triplet subunit. The subunit can form higher
multimers, of which the 12-mer (4 × 3) is thought to be the most
abundant in serum. The inset (right) shows a typical western blot
after electrophoresis of L-ficolin under nonreducing conditions.
possesses three inner binding sites (S2, S3, S4) that are
located on both sides of a cleft between the upper parts
of the protomers. It is S3 that is mainly responsible for
binding acetylated structures and also binds 1,3-β-glucans
with assistance from the minor site, S4. The innermost S2
has aﬃnity for galactose. The L-ficolin recognition groove
with its contiguous subsites (S2–S4) is reminiscent of the
peptidoglycan binding proteins of invertebrates [19].
The ficolins, collectins, and complement component C1q
all have a similar 3-dimensional shape suited to function
as multivalent recognition molecules with increased aﬃnity
for ligands achieved by multiple protein-oligosaccharide
interactions. It is noteworthy that L-ficolin possesses a semi-
open structure intermediate between the compact assembly
of C1q and the wide open arrangement of MBL which has
little interaction between the lectin domains and a buried
surface 8% the size of that of C1q [19].
The collagen-like region is responsible for the formation
of the helical tails of the molecule and also for functional
signalling. In particular, the lysine-57 residue is a key
component of the binding site for MBL-associated serine
proteases and also for calreticulin, a putative comple-
ment/collectin/ficolin receptor on phagocytes [31].
4. Biological Properties
4.1. Biochemical Specificity. L-ficolin was reported to bind to
mannan, mannan-Sepharose, and GlcNAc-BSA in a calcium-
dependent manner [2], whereas other workers described
calcium-independent binding to GlcNAc-Sepharose and
elution with GlcNAc [3]. L-ficolin also bound to CNBr-
activated (but underivatized) Sepharose blocked with Tris.
Since L-ficolin did not bind to mannan coupled to
“Emphase” (a polyacrylamide derivative) [32], it seems likely
the aﬃnity chromatography was achieved with Sepharose
(i.e., polygalactose) not mannan; this interaction was possi-
bly mediated by binding site S2. The inconsistency regarding
calcium is to some extent explained by the observation that
L-ficolin bound to GlcNAc-Sepharose or CysNAc-Sepharose
beads not only in the presence of calcium but also in the
absence of calcium at high NaCl concentrations [33]. Given
that X-ray crystallography has shown that the ancestral (S1)
calcium-associated binding site does not bind galactose or
acetylated sugars, it appears that the other binding sites are
influenced indirectly by their ionic environment.
It is clear that L-ficolin binds not just to acetylated
sugars but also to nonsaccharide acetylated compounds [33].
Nevertheless, glycan array studies have established that L-
ficolin does not bind to most acetylated oligosaccharides
found on mammalian glycoconjugates [34]. Rather, L-ficolin
has complex recognition requirements and binding probably
requires the presence of two or more acetylated sugar groups
presented in an appropriate conformation. In another glycan
array study, L-ficolin preferentially recognised disulphated
N-acetyllactosamine and tri- and tetrasaccharides containing
terminal galactose or N-acetylglucosamine and binding
was sensitive to the orientation of the bond between N-
acetyllactosamine and the adjacent saccharide [35].
L-ficolin is the major 1,3-β-glucan-binding protein in
human plasma [18] and can bind to lipoteichoic acid [36].
Potentially, therefore, L-ficolin could bind to a wide variety
of fungi and Gram-positive bacteria. L-ficolin recognises
and binds to the viral envelope glycoproteins (E1 and E2)
of the hepatitis C virus and triggers the lectin pathway
of complement by binding to a virally infected human
hepatoma cell line [37].
L-ficolin also appears to bind human DNA, suggesting a
mechanism for attaching to apoptotic or necrotic autologous
cells and thus promoting the removal of dead and moribund
cells and tissues [38]. It has already been mentioned that
L-ficolin can bind to a protein, elastin [4], and a lipid [5].
Most significantly, it can bind to the pentraxins, C-reactive
protein [39], pentraxin 3 (PTX3) [40], and serum amyloid P
component (J. D. Chalmers, unpublished).
4.2. Microbial Specificity. L-ficolin has been found to bind
to the Gram-negative bacteria, Salmonella typhimurium
(Ra strain) [2], Escherichia coli [41], and Pseudomonas
aeruginosa [42], as well as the Gram-positive species, (cap-
sulated) Staphylococcus aureus and streptococci including the
pneumococcus [33, 43, 44]. All interactions were partially
sensitive to GlcNAc. L-ficolin binding to the intracellular
bacterium Mycobacterium bovis has also been reported
[45]. Additionally, binding to Haemophilus influenzae and
Moraxella catarrhalis has been observed (J. D. Chalmers,
unpublished).
Binding of L-ficolin to the protozoan causing Chagas’
disease, Trypanosoma cruzi, has been demonstrated [46]
and to the intestinal protozoan Giardia lamblia [47]. It
also binds the opportunistic fungal pathogen, Aspergillus
fumigatus [40]. This last interaction can be partially inhibited
by GlcNAc or Curdlan (a β-1,3-glucose polymer).
The L-ficolin-mediated response to A. fumigatus is
enhanced by calcium-independent binding to PTX3 [40].
Similar synergy was observed between L-ficolin and C-
reactive protein in response to P. aeruginosa [42]. These
appear to be impressive examples of how L-ficolin can com-
bine with pentraxins to amplify antimicrobial recognition
and eﬀector mechanisms.
4.3. Complement Activation. L-ficolin is one of the few mol-
ecules known to activate the lectin pathway of complement
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activation [48]. This arises after forming a complex with
MBL-associated serine proteases (MASP)-1, -2, and -3, of
which MASP-2 is crucial for complement activation. MASP-
2 binding takes place at a site on the collagen-like region [31].
L-ficolin-MASP-2 interaction leads to activation of the latter,
enabling it to cleave complement components C2 and C4 in
a manner similar to the C1q, r, s complex of the classical
pathway initiated by antigen-antibody formation. The roles
ofMASP-1 and its alternatively spliced gene productMASP-3
are less clear, but evidence is accumulating that MASP-1 may
link complement to the coagulation system [49–53] as well
as collaborating with MASP-2 in the generation of the C3
convertase [54, 55]. MASP-3 is primarily found complexed
to H-ficolin and appears to regulate complement activation
mediated by the latter [56].
The other activators of MASP-2 and hence the lectin
pathway are the other human ficolins (M- and H-ficolin)
and the collectins, MBL and CL-11/CL-K1 [16, 17]. In so far
as they have been directly compared, H-ficolin emerged as
the most potent complement activator, at least as measured
in vitro by a particular C4 deposition assay [15]. L-ficolin
and MBL were similar, but had only half the complement
activation capacity of H-ficolin.
Unsurprisingly, L-ficolin has been shown to possess
opsonic activity by enhancing phagocytosis of Salmonella
by human neutrophils [2]. It can also promote the phago-
cytosis of Pseudomonas aeruginosa [42] and Streptococcus
pneumoniae (J. D. Chalmers, unpublished). Although such
opsonisation may be mediated by complement activation, it
has also been suggested that L-ficolin can opsonise bacteria
by binding calreticulin on phagocytes via its collagen-like
domain [31].
L-ficolin can cooperate with pentraxins to opsonise
bacteria and initiate the lectin pathway, as was mentioned
earlier.
Two reports support the view that L-ficolin can opsonise
autologous dead or dying cells and cellular debris [38, 57].
Kuraya et al. [57] concluded that L-ficolin binds to apoptotic
cells and activates complement via the lectin pathway. Jensen
et al. [38], however, observed binding to necrotic but not
apoptotic cells, and only at supraphysiological concentra-
tions of ≥20 μg/mL. High concentrations of L-ficolin also
promoted the uptake of necrotic Jurkat cells by monocyte-
derived macrophages in a phagocytosis assay [38]. Many
molecules have been described as binding to apoptotic cells,
however, and we have no idea of their relative physiological
significance in vivo.
5. L-Ficolin in Health and Disease
5.1. L-Ficolin in Healthy Subjects. In healthy adult individu-
als, the distribution of serum L-ficolin is perfectly Gaussian,
so the mean and median are exactly the same. That value has
generally been reported to be between 3 and 4 μg/mL [58]
although more recently it has been determined at 5.4 μg/mL
[25]. A complicating consideration is that purified L-ficolin
is very labile (unlike in serum); if anything other than
a recently isolated preparation is used as a standard, the
values obtained from the calibration curve will be higher
than the true values. There is also scope for discrepancy
between immunoassayed protein and a measurement based
on activity. However, in general, we have found broadly
similar values to be obtained with either acetylated BSA or
anti-L-ficolin antibody (clone GN4) as solid-phase capture
agent combined with the same labelled detection antibody
(clone GN5).
Most normal values fall within the range 1000 to
6000 ng/mL, although occasionally much higher values are
detected. No value much below 1000 ng/mL has been
detected in a healthy adult; therefore, absolute L-ficolin
deficiency has not been shown to exist. From genetic
studies [21], a homozygous frameshift mutation in exon 8
(rs28357091; Ala264fs; FCN2-D) would be expected to give
total deficiency, but this has not yet been found.
Normal values are generally lower in antenatal (cord
blood) sera [3, 59–61] and correlate with gestational age,
at least until shortly before term [60]. Only one study
has investigated serum L-ficolin throughout life [61]. The
highest values were found between 1 and 4 years of life
(median 11300 ng/mL), then dropped during later childhood
(4–16 years, median 8660 ng/mL) before reaching a stable
adult level (median 3370) after 16 years of age. Although
Sallenbach et al.’s values [61] were in good agreement with
our and others’ adult data and reasonably close agreement
for antenatal data, their elevated values for later childhood
were at variance with our finding of similar-to-adult values
for such children [62].
Although no absolute deficiency of L-ficolin has yet been
discovered, it seems possible that relative deficiency (“insuf-
ficiency”) defined by low serum L-ficolin ± immunogenetics
could contribute to disease susceptibility. Unfortunately, the
disease process itself (or treatment) might aﬀect circulating
L-ficolin, as has been found for patients with haematological
malignancies [26], preeclampsia [63], and sepsis (D. C.
Kilpatrick, unpublished).
5.2. General Infections. L-ficolin insuﬃciency was associated
with perinatal infections in preterm Polish babies [60].
In a cohort of over 1800 consecutive deliveries, the rate
of perinatal infections in babies with cord blood L-ficolin
<1000 ng/mL (the lowest 9%) was twice that of babies with
higher concentrations (13.7% versus 7.7%; P < 0.01). This
relationship was not independent of gestational age and
birthweight, but suggests that L-ficolin insuﬃciency could
be one of several factors that contribute to the adverse
consequences of prematurity and low birthweight [60].
Schlapback et al. [64], however, found no significant
relationship between low cord blood L-ficolin and sepsis
in 47 premature infants. This was despite finding sig-
nificant relationships between low H-ficolin and Gram-
positive sepsis and between low MBL and Gram-negative
sepsis. Incidentally, that study did confirm correlations
between L-ficolin concentration and both gestational age
and birthweight. It is possible that study was underpowered
for L-ficolin: for Gram-negative sepsis, 47% (7/15) of the
patients had low (<1000 ng/mL) L-ficolin compared with
23% (22/94) of infection-free, matched controls (P < 0.07)
[64].
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Uraemic patients have an increased susceptibility to
infection, and peritonitis is a common complication in
patients on continuous ambulatory peritoneal dialysis
(CAPD). The +6359 C>T variant in the FCN2 gene, causing
a Thr  Met alteration and a concomitant decrease in lectin
activity, was found to be commoner in CAPD patients with
a history of staphylococcal peritonitis compared with CAPD
patients without such a history [65]. In the former, exit site
Staphylococcus aureus was also more prevalent [65].
Another clinical context of interest is that of chemother-
apy ± transplantation. MBL has been intensively studied in
this context with wildly diﬀering results [66, 67]. In our series
of haematological malignancy patients who were rendered
severely neutropenic, entirely negative results were obtained
for both L-ficolin and H-ficolin [26].
However, the situation appears to be very diﬀerent in the
context of liver transplantation, where the recipient assumes
the phenotype of the donor. The variant FCN2 +6359 allele
was associated with a doubling of the bacterial infection
risk within the first year following transplant, and the risk
was enhanced by coinheritance of MBL2 variant alleles [68].
Patients with one or more lectin pathway genetic variants
and infection had a much increased mortality rate which was
highly statistically significant [68]. As well as those bacterial
infections causing sepsis and pneumonia, the normal (high
lectin activity) FCN2 +6359 was associated with protection
from cytomegalovirus after liver transplantation [69]. Again,
the combination of FCN2 and MBL2 risk alleles conferred a
particularly high degree of susceptibility.
5.3. Respiratory Infections. There is a strong theoretical
basis to believe L-ficolin may be important in respiratory
infections. As discussed previously, L-ficolin binds to and
opsonises a wide variety of important respiratory pathogens
(including capsulated S. pneumoniae, S. aureus, P. aeruginosa,
H. influenzae and others). L-ficolin, like MBL, has been
found in the inflamed lung (induced sputum and bron-
choalveolar lavage fluid) in concentrations suﬃcient to cause
complement activation (J. D. Chalmers, unpublished).
In perhaps the first disease association study involving
L-ficolin, an association between L-ficolin insuﬃciency and
recurrent respiratory infections in children was reported.
This relationship was particularly marked for patients with
coexisting allergic disorders (mostly rhinitis and/or asthma
with high IgE) [70]. This preliminary observation prompted
a fresh, prospective study on children aged 1 to 16 years
(mean 8.9) to confirm or refute the previous retrospective
findings and to distinguish between infection and allergy
[62]. L-ficolin insuﬃciency was indeed significantly associ-
ated with asthma and/or allergic rhinitis in the context of
recurrent respiratory infections, but not with those allergic
disorders in the absence of infection or with recurrent
respiratory infections in the absence of allergy [62]. The
reason for this relationship is not clear, but it is possible that
L-ficolin confers some protection from microorganisms that
exacerbate allergic inflammation in the lung.
Another research group examined FCN2 variants in a
birth cohort followed up for 4 years. Analysis based on con-
structed haplotypes yielded no relationship with recurrent
respiratory infection. No serum L-ficolinmeasurements were
made [71].
Similarly negative immunogenetic results were obtained
in a study of invasive pneumococcal disease [72], but again
no serum L-ficolin data were obtained.
There was a clear association between low serum L-
ficolin and idiopathic bronchiectasis [73]. This has since
been confirmed in a much larger series, and there is evidence
to suggest the basis could lie in protection from colonisation
with Pseudomonas aeruginosa [74]. Certainly, low serum
L-ficolin in those patients identifies a clinical phenotype
associated with more severe disease and therefore with
poorer quality of life.
5.4. Other Infectious Diseases. The distribution of FCN2
haplotypes in leprosy patients diﬀered significantly from
healthy controls [75]. The authors interpreted their findings
as an indication that normal (relatively high) L-ficolin
concentrations protect against M. leprae infections, but
serum L-ficolin was not actually measured.
A comparison of mild and severe Plasmodium falciparum
malaria revealed that serum L-ficolin concentration is high-
est during acute severe disease, but this diﬀerence was not
reflected in the distribution of the FCN2 haplotypes [76].
In contrast, the distribution of FCN2 haplotypes was
altered in cutaneous leishmaniasis patients when compared
with healthy controls [77]. Haplotypes expected to confer
normal concentrations of L-ficolin were commoner in
the controls, but again serum L-ficolin was not actually
measured.
5.5. Pregnancy Disorders. A small proportion of women who
had experienced recurrent miscarriage had serum L-ficolin
values below the lower limit of normal [59]. These patients
were sampled at a single point in time, and a longitudinal
study would be required to determine if those low values
were stable. It would also be instructive to learn if and how
L-ficolin varied during pregnancy in such patients.
According to Wang and coworkers [63], serum L-ficolin
increases several-fold during normal pregnancy, although it
is not clear whether a direct comparison was made between
pregnant and nonpregnant subjects. (Moreover, van de Geijn
et al. [78] reported that serum L-ficolin was not influenced
by pregnancy.) Certainly, Wang et al. found L-ficolin levels to
be significantly lower in preeclamptic pregnancies compared
with uncomplicated pregnancies of similar gestational age.
Postnatal placentae from preeclamptic pregnancies con-
tained higher concentrations of L-ficolin in lysates, and
more intense immunohistochemical staining was observed
in syncytiotrophoblast. The co-expression of L-ficolin and
Ras protein in preeclamptic syncytiotrophoblast was noted.
The authors interpret those observations as evidence of
consumption of L-ficolin by apoptotic trophoblast causing
depletion in the circulation.
5.6. Miscellaneous Disorders. The distribution of FCN2 vari-
ants was found to be altered in poststreptococcal disease
[79]. A haplotype associated with low levels of L-ficolin
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Table 3: Some disease associations of L-ficolin insuﬃciency.
Disease Associated with Reference
Perinatal infections Low serum L-ficolin [60]
Staphylococcal
peritonitis
FCN2 +6359 variant allele
(FCN2-B)
[65]
Bacterial infections
following liver
transplantation
FCN2 +6359 variant allele
(FCN2-B)
[68]
Childhood infections
combined with allergic
diseases
Low serum L-ficolin [62, 70]
Idiopathic
bronchiectasis
Low serum L-ficolin [73, 74]
Preeclampsia Low serum L-ficolin [63]
Chronic rheumatic heart
disease
Promoter haplotype GGA [79]
was slightly but significantly more frequent in patients
with chronic rheumatic heart disease (CRHD) compared
with healthy controls. Conversely, another haplotype was
commoner in controls than in either CRHD or rheumatic
fever patients. Since L-ficolin can readily bind to Strepto-
coccus pyogenes and thereby activate complement [44], it is
conceivable that these immunogenetic diﬀerences are related
to an altered innate response.
A similar FCN2 investigation in Behcet’s disease was
essentially negative [80] as was the outcome of serum L-
ficolin measurements in sarcoidosis [81]. Nevertheless there
was a trend towards lower circulating L-ficolin in sarcoid
patients, in contrast to an increase noted for MBL.
Immunohistochemical evidence for L-ficolin involve-
ment in IgA nephropathy has been found [82], but not in
renal allograft rejection [83].
The clearest associations of L-ficolin insuﬃciency with
disease susceptibility are summarised in Table 3.
6. Animal Studies
Animal work, though of indirect relevance to clinical
situations, often provides valuable supplementary evidence
concerning the function of human molecules. For example,
native (plasma-derived) and recombinant porcine ficolin-α
was found to neutralise porcine reproductive and respiratory
virus (a major pathogen of swine) in vitro in a GlcNAc-
dependent manner [84]. However, variant alleles of ficolin-
α were not associated with common infectious diseases
(pneumonia, enteritis, serositis, septicemia) at necropsy,
despite significant associations with MBL-A, MBL-C, and
surfactant protein A [85]. Of more tenuous significance was
the finding that a chimeric molecule combining the lectin
domain of MBL and the collagen-like region of L-ficolin had
enhanced protective activity towards Ebola virus than either
of the parent molecules [86].
Ficolin-A-deficient knockout mice have been established.
Survival of these mice after infection with Streptococcus
pneumoniae was reduced compared with that of wild-type
mice [87], but the phenotype of the knockout mice has not
been described in detail.
Human L-ficolin cDNA has been cloned into an expres-
sion plasmid and used in a murine model of Salmonella
typhimurium infection [88]. Administration of L-ficolin in
that form protected mice from a potentially lethal challenge
with Salmonella, with bacterial counts dramatically reduced
a week after infection compared with empty-vector-treated
controls. The recombinant L-ficolin enhanced monocyte
phagocytosis of Salmonella in a dose-dependent manner
[88].
7. Conclusions
Human L-ficolin is a unique plasma recognition molecule
with a broad specificity for microorganisms. It is capable
of complementing collectins (such as MBL) and pentraxins
in forming a battery of protective molecules constituting
the first line of defence. Its functional activities are likely
to be mediated through the lectin pathway of complement
activation. Although clinical research involving L-ficolin is
still in its infancy, evidence is emerging that insuﬃciency
of L-ficolin might increase susceptibility to respiratory
infections. In particular, the possibility that L-ficolin is a key
factor in protection from Pseudomonas aeruginosa warrants
further investigation.
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